TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18414066

Group type: EXPERIMENTAL
Intervention: High salt diet (3.86 g, 168 mmol/24 hours sodium)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low salt diet (1.3 g, 56 mmol/24 hours sodium)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Plasma 24,25-dihydroxyvitamin D concentrations
Number of subjects: 21
Study: 15812738

Group type: EXPERIMENTAL
Intervention: Structured educational/counseling sessions by telephone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Structured educational/counseling sessions in clinic
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study: 12459399

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (0.625 mg) plus medroxyprogesterone acetate (2.5 mg) daily
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 2763
Study: 10488696

Group type: EXPERIMENTAL
Intervention: HCV-RNA positive patients
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Higher present age
Number of subjects: 45
Study: 8945026

Group type: EXPERIMENTAL
Intervention: DDDR mode
Number of subjects: 63

Group type: COMPARATOR
Intervention: DDD mode
Number of subjects: 63
Study: 1760824

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN) 2 x 40 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atenolol (AT) 100 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined administration of IS-5-MN and AT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31767518

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg at Weeks 0, 2, 4, and 6, followed by placebo at Week 8, alirocumab at Week 10, placebo at Weeks 12 and 14.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo at Week 8, followed by alirocumab at Week 10, placebo at Weeks 12 and 14.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Alirocumab 150 mg and placebo.
Number of subjects: 23
Study: 29130954

Group type: EXPERIMENTAL
Intervention: Tolvaptan (≤15 mg/day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Increased furosemide (≤40 mg/day)
Number of subjects: 81
Study: 26401089

Group type: EXPERIMENTAL
Intervention: Moxifloxacin-based sequential therapy (MBST)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Hybrid therapy
Number of subjects: 284
Study: 23881284

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 0
Study: 21928714

Group type: EXPERIMENTAL
Intervention: Topical cream of Calendula officinalis extract
Number of subjects: 21

Group type: COMPARATOR
Intervention: Base cream (control)
Number of subjects: 21
Study: 19720909

Group type: COMPARATOR
Intervention: Paclitaxel 135 mg/m(2) over 24 hours plus Cis 50 mg/m(2) day 2 every 3 weeks (PC)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Vinorelbine 30 mg/m(2) days 1 and 8 plus Cis 50 mg/m(2) day 1 every 3 weeks (VC)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m(2) day 1 and 8 plus Cis 50 mg/m(2) day 1 every 3 weeks (GC)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Topotecan 0.75 mg/m(2) days 1, 2, and 3 plus Cis 50 mg/m(2) day 1 every 3 weeks (TC)
Number of subjects: 513
Study: 17262850

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 943

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 943
Study: 15364659

Group type: EXPERIMENTAL
Intervention: Service-learning training program at ADS
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group serving at other S-L sites
Number of subjects: 5
Study: 11443156

Group type: EXPERIMENTAL
Intervention: 20 mg/day pegvisomant
Number of subjects: 7
Study: 9875631

Group type: EXPERIMENTAL
Intervention: HCV RNA detection in livers
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HGV RNA detection in livers
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HBV DNA detection in livers
Number of subjects: 26

Group type: COMPARATOR
Intervention: Detection of HCV RNA and HBV DNA in toxic or autoimmune fulminant hepatic failure
Number of subjects: 26
Study: 8018795

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of GRF (1 micrograms/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2730280

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30129089

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 774

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 774
Study: 28349250

Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 25424146

Group type: EXPERIMENTAL
Intervention: EpiFix
Number of subjects: 60

Group type: COMPARATOR
Intervention: Apligraf
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 23296629

Group type: EXPERIMENTAL
Intervention: Pancreatic stone protein (PSP)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: soluble human triggering receptor expressed on myeloid cells-1 (sTREM-1)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Macrophage migration inhibitory factor (MIF)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Combination of PSP (>9 ng/ml) and PCT (>2 ng/ml)
Number of subjects: 137
Study: 21955225

Group type: EXPERIMENTAL
Intervention: T40/A10
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: T80/A10
Number of subjects: 947

Group type: COMPARATOR
Intervention: A10
Number of subjects: 947
Study: 19393142

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 0
Study: 16289171

Group type: EXPERIMENTAL
Intervention: Selective REM sleep deprivation by selective REM sleep awakenings
Number of subjects: 107

Group type: COMPARATOR
Intervention: Woken during stage 2 NREM sleep in matched frequency
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Physiological REM sleep augmentation via REM sleep rebound after selective REM sleep deprivation
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Pharmacological REM sleep augmentation by administering an acetylcholinesterase inhibitor
Number of subjects: 107
Study: 12888122

Group type: EXPERIMENTAL
Intervention: 0.5 mg fludrocortisone p.o.
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.2 mg aldosterone i.v.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11038029

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 8689991

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.4, 0.8, and 1 mg bolus injections followed by 1 mg/h infusion for 3 hours)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (3 hours infusion)
Number of subjects: 32
Study: 1411891

Group type: EXPERIMENTAL
Intervention: Closed vault technique using absorbable staples
Number of subjects: 102

Group type: COMPARATOR
Intervention: Open vault technique
Number of subjects: 102
Study: 4059478

Group type: EXPERIMENTAL
Intervention: Stress monitoring and intervention program
Number of subjects: 453

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 453
Study: 30551121

Group type: EXPERIMENTAL
Intervention: 0.3 g · kg‐1 BW NaHCO3
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.1 g · kg‐1 BW NaHCO3
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (0.3 g · kg‐1 BW placebo)
Number of subjects: 21
Study: 29097329

Group type: EXPERIMENTAL
Intervention: 2‐day zero‐calorie diet with water provided ad libitum
Number of subjects: 11

Group type: COMPARATOR
Intervention: 2‐day usual diet
Number of subjects: 11
Study: 26780639

Group type: EXPERIMENTAL
Intervention: Framed Task (FT) reporting only lung nodule/s
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unframed Task (UFT) to report any abnormality
Number of subjects: 10
Study: 22578920

Group type: EXPERIMENTAL
Intervention: End-fire transrectal ultrasound probe
Number of subjects: 297

Group type: COMPARATOR
Intervention: Side-fire transrectal ultrasound probe
Number of subjects: 297
Study: 20955445

Group type: EXPERIMENTAL
Intervention: Pneumatic dilation
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Laparoscopic Heller myotomy with fundoplication (LHM+Fp)
Number of subjects: 94

Group type: COMPARATOR
Intervention: LHM+Fp
Number of subjects: 94
Study: 18033807

Group type: EXPERIMENTAL
Intervention: Mild ovarian stimulation/GnRH antagonist co-treatment with single embryo transfer
Number of subjects: 404

Group type: COMPARATOR
Intervention: Standard stimulation/GnRH agonist long protocol with transfer of two embryos
Number of subjects: 404
Study: 16372578

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 20 mg three times daily, orally
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Routine treatment plus TMZ
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 60
Study: 12523089

Group type: EXPERIMENTAL
Intervention: Patient education (two two-hour group sessions followed by one or two individual sessions administered by a nurse and a physiotherapist)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Patient education (5% improvement in FEV1)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Patient education (NNE to make one person symptom free)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (ordinary outpatient care)
Number of subjects: 78
Study: 9607046

Group type: EXPERIMENTAL
Intervention: Triviraten Berna Vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: MMR-Vax
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMR-Vax and Triviraten Berna (reimmunization)
Number of subjects: 0
Study: 7895354

Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy
Number of subjects: 305

Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty
Number of subjects: 305
Study: 2115892

Group type: EXPERIMENTAL
Intervention: Pimozide (2-18 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Haloperidol (2-15 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No drugs
Number of subjects: 33
Study: 345410

Group type: EXPERIMENTAL
Intervention: Metronidazole 1,000 mg daily for two months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo for two months
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Metronidazole in patients with colonic involvement
Number of subjects: 22
Study: 31434605

Group type: EXPERIMENTAL
Intervention: E-cigarettes
Number of subjects: 886

Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 886
Study: 29394971

Group type: EXPERIMENTAL
Intervention: Medication and weight-bearing exercises
Number of subjects: 274

Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 274
Study: 27723228

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 6000
Study: 23954029

Group type: EXPERIMENTAL
Intervention: Use of biomarkers to increase the sample fraction that would develop Alzheimer's disease from 0.5 to 0.8
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Assuming homogeneity of parameter estimates
Number of subjects: 200
Study: 22918094

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 to 0.75 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral tramadol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral triclofos
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral zolpidem
Number of subjects: 60
Study: 20063224

Group type: EXPERIMENTAL
Intervention: IV fluid group (lactated ringers at 250 ml per hour)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 80
Study: 17655695

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) + HBV vaccine (40 mug HBV(vac) after 5 mug/kg GM-CSF injection)
Number of subjects: 102

Group type: COMPARATOR
Intervention: HBV vaccine (40 mug HBV(vac) intramuscularly)
Number of subjects: 102
Study: 16338252

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group (normolipidemic)
Number of subjects: 232
Study: 11939915

Group type: EXPERIMENTAL
Intervention: Propofol 1% Fresenius
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diprivan 1%
Number of subjects: 60
Study: 10419609

Group type: EXPERIMENTAL
Intervention: Early amniotic fluid (EA) at 11+0‐12+6 weeks
Number of subjects: 4107

Group type: COMPARATOR
Intervention: Mid amniotic fluid (MA) at 15+0‐16+6 weeks
Number of subjects: 4107
Study: 8819183

Group type: EXPERIMENTAL
Intervention: Salmeterol (25 + 50 + 100 micrograms)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Salbutamol (100 + 200 + 400 micrograms)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Propranolol (400 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2048661

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 7295883

Group type: EXPERIMENTAL
Intervention: Betamethasone tablet formulation A (2 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Betamethasone tablet formulation B (2 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate solution C (2 mg)
Number of subjects: 9
Study: 31638946

Group type: EXPERIMENTAL
Intervention: Menstrual cup arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cash transfer arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cups and cash combined intervention arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study: 28809995

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 25583754

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg/linagliptin 5 mg
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/linagliptin 5 mg
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 642
Study: 24886516

Group type: EXPERIMENTAL
Intervention: Web-based only
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Basic nurse support (3 sessions in 3 months)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Regular nurse support (7 sessions in 6 months)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 179
Study: 22341370

Group type: EXPERIMENTAL
Intervention: Δ9-tetrahydrocannabinol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 20598270

Group type: EXPERIMENTAL
Intervention: Training with feedback on gender-marked noun phrases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training with feedback
Number of subjects: 0
Study: 17055561

Group type: EXPERIMENTAL
Intervention: Community-based walking intervention (n=102)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Usual primary health care (Control group, n=100)
Number of subjects: 202
Study: 15475599

Group type: EXPERIMENTAL
Intervention: Breathing depth at 80% of total lung capacity (TLC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Breathing depth at 90% of total lung capacity (TLC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Breathing depth at 100% of total lung capacity (TLC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Deep breaths of any amplitude
Number of subjects: 12
Study: 12384623

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Bare Bx velocity stent
Number of subjects: 1100
Study: 10445557

Group type: EXPERIMENTAL
Intervention: alpha-interferon (5 MU/m2 three times weekly for 6 months)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 64
Study: 8695970

Group type: EXPERIMENTAL
Intervention: MFP at the dose of 20 mg F-equivalents + 600 mg calcium/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: 500 mg/day of oral calcium
Number of subjects: 42
Study: 2392980

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Beta 1-selective beta blocker (metoprolol)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Beta 1-nonselective beta blocker (propranolol)
Number of subjects: 30
Study: 7308268

Group type: EXPERIMENTAL
Intervention: muzolimine 240 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: furosemide 240 mg
Number of subjects: 8
Study: 31087185

Group type: EXPERIMENTAL
Intervention: Eldecalcitol 0.75 μg
Number of subjects: 265

Group type: COMPARATOR
Intervention: Alfacalcidol 1.0 μg
Number of subjects: 265
Study: 28050642

Group type: EXPERIMENTAL
Intervention: Solifenacin (10 mg)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Trospium chloride (60 mg)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo (one tablet)
Number of subjects: 210
Study: 25872802

Group type: EXPERIMENTAL
Intervention: 200,000 IU VAS at <3 d and placebo at 6 weeks postpartum
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Placebo at <3 d and 200,000 IU VAS at 6 weeks postpartum
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 200,000 IU VAS, both at <3 d and 6 weeks postpartum
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo, both at <3 d and 6 weeks postpartum
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Infant blood samples at 2 and 4 months of age
Number of subjects: 128
Study: 22658571

Group type: EXPERIMENTAL
Intervention: Combined aerobic training (AT) with resistance training (RT) and inspiratory muscle training (IMT) (ARIS)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 27
Study: 22136279

Group type: EXPERIMENTAL
Intervention: Chungkookjang (CKJ) pills, 35 g per day for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo pills, 35 g per day for 3 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chungkookjang (CKJ) pills
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 60
Study: 18801775

Group type: EXPERIMENTAL
Intervention: Worn shoes
Number of subjects: 24

Group type: COMPARATOR
Intervention: New shoes
Number of subjects: 24

Group type: COMPARATOR
Intervention: Different footwear types (air/gel/spring)
Number of subjects: 24
Study: 16518360

Group type: EXPERIMENTAL
Intervention: Fluid-based system (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional ultrasound (Group 2)
Number of subjects: 60
Study: 16961791

Group type: COMPARATOR
Intervention: Balanced amino acid condition (L-tryptophan present)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion condition (L-tryptophan omitted)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion condition
Number of subjects: 73
Study: 15242999

Group type: EXPERIMENTAL
Intervention: Laparoscopic electrocautery of the ovaries followed by CC and recombinant FSH (rFSH)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Recombinant FSH (rFSH)
Number of subjects: 168
Study: 11049886

Group type: EXPERIMENTAL
Intervention: Nitrous oxide anesthesia
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-nitrous oxide anesthesia
Number of subjects: 90
Study: 8969629

Group type: EXPERIMENTAL
Intervention: Intravenous disodium EDTA (3 g)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1534639

Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine stored at 4 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine heated for 1 week at 45 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine heated for 1 month at 37 degrees C
Number of subjects: 0
Study: 3975851

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (doxorubicin, cyclophosphamide, and high-dose methotrexate)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No chemotherapy (control group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Chemotherapy (among entire cohort)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Radiotherapy (all patients received)
Number of subjects: 37
Study: 30865144

Group type: EXPERIMENTAL
Intervention: COPing with and CAring for infants with special needs (COPCA) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Another infant physical therapy
Number of subjects: 0
Study: 28096005

Group type: EXPERIMENTAL
Intervention: Lullaby group (n=26) listened to male lullaby via headphones for 20 minutes daily over 3 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (n=26) received headphones without sound
Number of subjects: 52
Study: 25981087

Group type: EXPERIMENTAL
Intervention: Multifaceted and culturally appropriate intervention
Number of subjects: 1416

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1416
Study: 23440076

Group type: EXPERIMENTAL
Intervention: Active Mind cognitive-training program (8 sessions of 1 hour each)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual group activities provided by DECCs
Number of subjects: 200
Study: 21252962

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 20
Study: 19021727

Group type: EXPERIMENTAL
Intervention: Communication skills course (test group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Problem-based workshops (control group)
Number of subjects: 26
Study: 17347071

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Skinfold Thickness
Number of subjects: 210